Evexia Comprehensive Diabesity Panel

Overview:

Obesity is strongly associated with the pathogenesis of type 2 diabetes, hypertension, and cardiovascular disease.  Recent studies have suggested that adipose tissue may play a crucial role in the development of these conditions and their complications through the secretion of various bioactive molecules referred to as adipokines.

Prediabetes refers to impaired fasting glucose or impaired glucose tolerance.  It is characterized by glucose levels that are higher than normal but not elevated enough to be diagnostic of diabetes.  Recent data from the Centers for Disease Control and Prevention suggest that an estimated 86 million adults in the US had prediabetes in 2012. Usually, those who have prediabetes do not have any symptoms.  However, if no action is taken to lower their glucose level, they are at an increased risk of developing diabetes within about ten years.  The early detection of risk factors, including hidden risks, equates to a more timely intervention to stop or delay the progression to diabetes before it becomes more complex to manage.

The Evexia Diagnostics Comprehensive Diabetesity Panel can help identify individuals with insulin resistance, prediabetes, metabolic syndrome, and cardiovascular disease risk.  This panel incorporates a complete blood count, a comprehensive metabolic panel, a thyroid panel, and a complete urinalysis.  Also included are tests for inflammation and oxidative stress (GGT, F-2 isoprostane/creatinine ratio, uric acid, glutathione, and high-sensitivity C-Reactive Protein).  Adiponectin and leptin are a part of this panel along with markers of glucose regulation and metabolism that include hemoglobin A1c with average glucose, GlycoMark, and C-peptide.  Another critical component in this panel is a nutrient assessment of vitamin D, zinc, magnesium, as well as the advanced NMR LipoProfile.

Adipokines contribute to the pathophysiology of obesity-linked disorders through their abilities to modulate inflammatory and metabolic processes. Diminished levels of adiponectin are associated with the increased prevalence of obesity-linked cardiovascular diseases, including ischemic heart disease and peripheral artery disease.  Adiponectin is a plasma adipokine protein secreted specifically by adipose tissue. Leptin is used for the assessment of obesity, delayed puberty, and infertility.

GlycoMark testing provides an estimate of the patient's post-meal glucose over a one- to two-week period, making it ideal for intermediate-term monitoring of glycemic control in diabetic patients. GlycoMark testing can also help monitor the effectiveness of therapeutics targeting postprandial glucose and is a useful adjunct to routine A1c testing because it responds more rapidly and with greater sensitivity to hyperglycemia than A1c.

The NMR LipoProfile consists of the traditional lipid panel markers such as LDL-C, HDL-C, triglycerides, and total cholesterol.  However, it can help determine an individual's risk of heart disease, as well as guide decisions about what treatment may be best if there is borderline or high risk.  The NMR LipoProfile goes beyond the standard markers by measuring the particle size and number of HDL and LDL, as well as providing an Insulin Resistance Score.  The IR Score is a laboratory-developed index associated with insulin resistance and diabetes risk and can be used as one component of clinical assessment. Insulin resistance is the precursor to type 2 diabetes and manifests its earliest measurable abnormalities though changes in lipoproteins. The IR score may be a first alert to a heightened risk of developing T2DM.

This panel comes with a free* Functional Health Report when Evexia Nutraceuticals are recommended.  *A $5 fee is applied when recommendations other than Evexia Nutraceuticals are selected.